Avacta Group Plc provides a business update ahead of the Annual General Meeting (AGM) which will be held today, Wednesday, 26 June 2024. At the meeting, Christina Coughlin MD, PhD, CEO, and Shaun Chilton, Non-Executive Chairman, will make the following announcements on clinical and operational progress and the appointment of a new Non-Executive Board director. Avacta confirms that Arm 2 of the Phase 1 trialfor AVA6000, a peptide drug conjugate form of doxorubicin chemotherapy, has successfully completed its second cohort without dose limiting toxicities observed.

Patients are now being dosed in the third cohort. This puts Avacta on track to achieve its stated clinical objectives for 2H 2024. To support the progress of this trial, Avacta has appointed a Scientific Advisory Board of senior cancer experts and researchers.

In line with the previously announced evolution of the Board, Avacta also announces the following: The appointment of Darlene Deptula-Hicks to the position of Non-Executive Director, effective following the AGM. Darlene is an entrepreneurial financial leader with proven expertise in building strategic external partnerships to achieve business results and increase shareholder value, with expertise incapital markets as well as operational and commercial experience including product commercialization, supply chain, manufacturing and quality assurance. Tony Gardiner has stepped down from the Board of Directors with immediate effect.

The search for a new permanent CFO is underway and Tony will remain in the post to ensure an orderly transition. Formation of Scientific Advisory Board (SAB): Avacta also announces the creation of a Scientific Advisory Board to provide expert insight and guidance on the ongoing clinical development of AVA6000 and the pipeline, including the pre|CISION? platform.

The Board will be chaired byWilliam D. Tap MD, Chief of the Sarcoma Oncology Service at the Memorial Sloan Kettering Cancer Center in New York City. Dr. Tap will be joined by several colleagues in both the UK and US including: Robin Jones, MBBS, MRCPD, MD, Professor andGroup Leader in Sarcoma Clinical Trials at The Institute of Cancer Research and the Royal Marsden Hospital in London. Lee Cranmer, MD, PhD, Head of Sarcoma Oncology at the University of Washington and Fred Hutchinson Cancer Center, Seattle, Washington.

Robert Metcalf,MBChB MRCP PhD, Clinician Scientist in Experimental Cancer Medicine and Honorary Consultant in Head and Neck Cancer Oncology and Salivary Gland Cancer Expert at the Christie NHS Foundation Trust, Manchester. Alan Ho, MD, PhD, Clinician-Scientist andtranslational clinical researcher on the head/neck medical oncology service at Memorial Sloan Kettering Cancer Center, New York City. Andrea Napolitano, M.D., PhD.

Consultant Oncologist and Experimental Therapeutics Expert at the Institute for Cancer Research and Royal Marsden Hospital, London. Anthony Yu, MD, MS, Clinical Onco-Cardiologist specializing in the management of cardio-toxicities of approved and experimental therapeutics,Memorial Sloan Kettering Cancer Center, New York City.